For decades, Indian doctors have described obesity to patients as a lifestyle problem — something they can fix with willpower and diet. That framing is now officially outdated. The Endocrine Society of India (ESI) updated its clinical practice guidelines for obesity management in 2025, and the direction is clear: obesity is a complex chronic disease, not a character flaw. Here is what changed, and what it means for your OPD. Why the Shift Matters The old model treated obesity as a precondition — something you address only once it causes diabetes, hypertension, or heart disease. The new model treats excess adiposity with functional or clinical consequences as a medical condition requiring staging, treatment planning, and long-term follow-up. The cost of obesity in India was estimated at ₹2.5 trillion in 2019. Without intervention, direct medical costs for obesity-related comorbidities are projected to nearly double to ₹3.8 trillion by 2032. This is a public health and economic emergency. The Staging System You Should Know The new ESI guidelines align with a two-stage model: Stage 1 Obesity: BMI ≥23 kg/m² without appreciable impact on daily activity or organ function. Management is lifestyle-focused: dietary changes, physical activity, behavioural counselling. Stage 2 Obesity: BMI ≥23 kg/m² plus excess waist circumference or waist-to-height ratio, AND either obesity-related symptoms (breathlessness, palpitations, musculoskeletal pain) or at least one comorbidity (T2DM, hypertension, dyslipidaemia). At this stage, pharmacotherapy or surgical intervention may be appropriate. This approach is especially important for Indian patients because of the thin-fat phenotype. Key Takeaways from the 2025 ESI Obesity Guidelines for Your OPD Reframe Obesity in Consultations Communicate clearly that obesity is a chronic, complex disease, not a lifestyle failure. Document obesity as a diagnosis in the file, not just as a risk factor. Use Staging, Not Just BMI Labels Stage 1 Obesity: BMI ≥23 kg/m², no major functional/organ impact → focus on lifestyle, diet, physical activity, behavioural counselling. Stage 2 Obesity: BMI ≥23 kg/m² plus high waist/WHtR and symptoms or ≥1 comorbidity (T2DM, HTN, dyslipidaemia, etc.) → consider pharmacotherapy and, where appropriate, surgical options. Actively Look for the Thin-Fat Phenotype Do not reassure solely on the basis of a “normal” BMI. Measure waist circumference and calculate waist-to-height ratio (WHtR) for all adults. WHtR >0.5 or large waist in a BMI 18.5–22.9 patient should trigger metabolic risk assessment (fasting glucose, HbA1c, lipids, BP, MASLD risk). Apply Indian-Specific Cut-offs in Routine Practice Overweight: BMI ≥23 kg/m² Obese Class I: BMI ≥25 kg/m² Obese Class II: BMI ≥30 kg/m² Abnormal waist: ≥80 cm (women), ≥90 cm (men) WHtR >0.5 → strong cardiometabolic risk signal. Pharmacotherapy: Start Earlier in Stage 2 Indications: BMI >27 kg/m², or BMI >25 kg/m² with ≥1 comorbidity. Tirzepatide: when you need ~15–20% weight loss (e.g., severe obesity, high cardiometabolic burden). Injectable semaglutide: for ~10–15% weight loss targets. Oral semaglutide: option where injections are a barrier. Liraglutide (Saxenda): still usable but increasingly second-line to more potent agents. Use the BLACK framework when counselling on obesity drugs: B – Benefits: expected weight loss, metabolic gains, organ protection. L – Lifestyle: drugs augment, not replace, diet and activity. A – Administration: dose, titration, injection technique or oral timing. C – Contraindications: personal/family history of MTC, MEN2, pancreatitis, pregnancy, etc.